COTQF (Cotinga Pharmaceuticals) Debt-to-Equity : -0.12 (As of Jan. 2020)

View and export this data going back to 2007. Start your Free Trial

What is Cotinga Pharmaceuticals Debt-to-Equity?

Cotinga Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2020 was $0.36 Mil. Cotinga Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2020 was $0.00 Mil. Cotinga Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Jan. 2020 was $-2.98 Mil. Cotinga Pharmaceuticals's debt to equity for the quarter that ended in Jan. 2020 was -0.12.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cotinga Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

COTQF's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Cotinga Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Cotinga Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cotinga Pharmaceuticals Debt-to-Equity Chart

Cotinga Pharmaceuticals Annual Data

Trend

Apr10

Apr11

Apr12

Apr13

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Debt-to-Equity

Get a 7-Day Free Trial

-0.08

Cotinga Pharmaceuticals Quarterly Data
	Apr15	Jul15	Oct15	Jan16	Apr16	Jul16	Oct16	Jan17	Apr17	Jul17	Oct17	Jan18	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20
Debt-to-Equity	Get a 7-Day Free Trial															-	-0.08	-0.07	-0.10	-0.12

Competitive Comparison of Cotinga Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Cotinga Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cotinga Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cotinga Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cotinga Pharmaceuticals's Debt-to-Equity falls into.

Cotinga Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cotinga Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Apr. 2019 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.149	+	0)	/	-1.793
	=	-0.08

Cotinga Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Jan. 2020 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.359	+	0)	/	-2.982
	=	-0.12

Cotinga Pharmaceuticals (OTCPK:COTQF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Cotinga Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Cotinga Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cotinga Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cotinga Pharmaceuticals Inc (OTCPK:COTQF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C1P1

Website

http://www.cotingapharma.com

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

Cotinga Pharmaceuticals Headlines

From GuruFocus

Cotinga Pharmacueticals Announces Closing of Unit Offering

By GlobeNewswire GlobeNewswire • 05-22-2019

Cotinga Pharmaceuticals Reports Fiscal 2018 Third Quarter Financial and Operating Results

By GlobeNewswire GlobeNewswire • 04-03-2018